Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors
暂无分享,去创建一个
Thierry Soussi | Ulf Gyllensten | Ola Larsson | Adam Ameur | Johan Botling | Patrick Micke | Karolina Edlund | Ignas Bunikis | Magnus Sundström | A. Ameur | K. Edlund | U. Gyllensten | T. Soussi | O. Larsson | I. Bunikis | P. Micke | J. Botling | Bernard Leroy | M. Sundström | Bernard Leroy | B. Leroy
[1] C. Harris,et al. Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.
[2] G. Giaccone,et al. EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[3] S. Kern,et al. Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature , 2006, Cancer biology & therapy.
[4] A. Marchetti,et al. Assessing EGFR mutations. , 2006, The New England journal of medicine.
[5] P. Platzer,et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.
[6] P. Nederlof,et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.
[7] S. Kato,et al. The UMD TP53 database and website: update and revisions , 2006, Human mutation.
[8] I. Haviv,et al. Breast-Cancer Stromal Cells with TP 53 Mutations , 2008 .
[9] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[10] C. Ishioka,et al. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.
[11] S. Kern,et al. Elegance, silence and nonsense in the mutations literature for solid tumors , 2006, Cancer biology & therapy.
[12] Magali Olivier,et al. TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.
[13] I. Haviv,et al. Breast-cancer stromal cells with TP53 mutations. , 2008, The New England journal of medicine.
[14] S. Kato,et al. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations , 2005, Human mutation.
[15] S. Gabriel,et al. Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.
[16] R J DUBOS,et al. Health and disease. , 1960, JAMA.
[17] S. Chanock,et al. The devil is in the DNA , 2007, Nature Genetics.
[18] T. Frebourg,et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls , 2011, Modern Pathology.
[19] Thierry Soussi,et al. TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.
[20] A. Inga,et al. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] T. Soussi,et al. TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade , 2014, Human mutation.
[22] S. Kato,et al. Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection , 2006, Clinical Cancer Research.
[23] A. Fersht,et al. The tumor suppressor p53: from structures to drug discovery. , 2010, Cold Spring Harbor perspectives in biology.
[24] Karen H. Vousden,et al. p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.
[25] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[26] F. Pontén,et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.
[27] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[29] Thierry Soussi,et al. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination , 2008, Cancer biology & therapy.
[30] J. Halgunset,et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. , 2005, The Journal of molecular diagnostics : JMD.
[31] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[32] T. Soussi. Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. , 2011, Biochimica et biophysica acta.
[33] A. Fersht,et al. Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.
[34] Kylie L. Gorringe,et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas , 2008, Nature Genetics.